MicroRNA-361-5p Inhibits Tumorigenesis and the EMT of HCC by Targeting Twist1

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2020 Dec 31

PMID 33381597

Citations 12

Authors

Liang-Chun Yin

Gang Xiao

Rui Zhou

Xiao-Ping Huang

Ning-Lei Li

Can-Liang Tan

Feng-Jiao Xie

Jun Weng

Li-Xin Liu

Affiliations

Soon will be listed here.

Abstract

MicroRNA-361-5p (miR-361-5p) is a tumor suppressor miRNA that is dysregulated in several types of human cancer. However, the functional significance of miR-361-5p in hepatocellular carcinoma (HCC) is unclear. This study explored the biological function of miR-361-5p in regulating the progression of HCC and the underlying molecular mechanism. RT-qPCR analysis showed that miR-361-5p was downregulated in HCC tissues and cell lines. Functional analysis revealed that miR-361-5p acted as a tumor suppressor, inhibiting cell proliferation, migration, and invasion in HCC cell lines. Bioinformatics analyses identified Twist1 as a direct target of miR-361-5p, which was validated by dual-luciferase reporter assays, RT-qPCR, and western blotting. Rescue experiments indicated that Twist1 may mediate the tumor-suppressive effect of miR-361-5p in HCC cells, and this was supported by the effect of miR-361-5p on inhibiting the epithelial-mesenchymal transition (EMT) by targeting Twist1. This study is the first to suggest that miR-361-5p inhibits tumorigenesis and EMT in HCC by targeting Twist1. These findings are valuable for the diagnosis and clinical management of HCC.

Citing Articles

Exosomes-Promising Carriers for Regulatory Therapy in Oncology.

Jozwicka T, Erdmanska P, Stachowicz-Karpinska A, Olkiewicz M, Jozwicki W Cancers (Basel). 2024; 16(5).

PMID: 38473285 PMC: 10931160. DOI: 10.3390/cancers16050923.

Interaction between miR‑206 and lncRNA MALAT1 in regulating viability and invasion in hepatocellular carcinoma.

Wang J, Yao G, Zhang B, Zhao Z, Fan Y Oncol Lett. 2023; 27(1):5.

PMID: 38028177 PMC: 10665983. DOI: 10.3892/ol.2023.14138.

The pivotal role of EMT-related noncoding RNAs regulatory axes in hepatocellular carcinoma.

Ghionescu A, Sorop A, Dima S Front Pharmacol. 2023; 14:1270425.

PMID: 37767397 PMC: 10520284. DOI: 10.3389/fphar.2023.1270425.

Regulation of Hepatocellular Carcinoma Epithelial-Mesenchymal Transition Mechanism and Targeted Therapeutic Approaches.

Yuregir Y, Kacaroglu D, Yaylaci S Adv Exp Med Biol. 2023; 1450:93-102.

PMID: 37452258 DOI: 10.1007/5584_2023_781.

An in vitro approach to understand contribution of kidney cells to human urinary extracellular vesicles.

Barreiro K, Lay A, Leparc G, Tran V, Rosler M, Dayalan L J Extracell Vesicles. 2023; 12(2):e12304.

PMID: 36785873 PMC: 9925963. DOI: 10.1002/jev2.12304.

References

Sun J, Chen G, Xie Z . MicroRNA-361-5p Inhibits Cancer Cell Growth by Targeting CXCR6 in Hepatocellular Carcinoma. Cell Physiol Biochem. 2016; 38(2):777-85. DOI: 10.1159/000443033. View

Turco C, Donzelli S, Fontemaggi G . miR-15/107 microRNA Gene Group: Characteristics and Functional Implications in Cancer. Front Cell Dev Biol. 2020; 8:427. PMC: 7311568. DOI: 10.3389/fcell.2020.00427. View

Brummer A, Hausser J . MicroRNA binding sites in the coding region of mRNAs: extending the repertoire of post-transcriptional gene regulation. Bioessays. 2014; 36(6):617-26. DOI: 10.1002/bies.201300104. View

Feng Q, Dong Z, Zhou Y, Zhang H, Long C . miR-16-1-3p targets TWIST1 to inhibit cell proliferation and invasion in NSCLC. Bratisl Lek Listy. 2018; 119(1):60-65. DOI: 10.4149/BLL_2018_012. View

Mizuguchi Y, Takizawa T, Yoshida H, Uchida E . Dysregulated miRNA in progression of hepatocellular carcinoma: A systematic review. Hepatol Res. 2015; 46(5):391-406. DOI: 10.1111/hepr.12606. View

Bartel D . MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136(2):215-33. PMC: 3794896. DOI: 10.1016/j.cell.2009.01.002. View

Ma F, Zhang L, Ma L, Zhang Y, Zhang J, Guo B . MiR-361-5p inhibits glycolytic metabolism, proliferation and invasion of breast cancer by targeting FGFR1 and MMP-1. J Exp Clin Cancer Res. 2017; 36(1):158. PMC: 5683540. DOI: 10.1186/s13046-017-0630-1. View

Zhang S, Liu Z, Wu L, Wang Y . MiR-361 targets Yes-associated protein (YAP) mRNA to suppress cell proliferation in lung cancer. Biochem Biophys Res Commun. 2017; 492(3):468-473. DOI: 10.1016/j.bbrc.2017.08.072. View

Yang J, Roberts L . Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol. 2010; 7(8):448-58. PMC: 3926946. DOI: 10.1038/nrgastro.2010.100. View

10.

Yu H, Gao G, Cai J, Song H, Ma Z, Jin X . MiR-539 functions as a tumor suppressor in pancreatic cancer by targeting TWIST1. Exp Mol Pathol. 2019; 108:143-149. DOI: 10.1016/j.yexmp.2019.04.012. View

11.

Georgakopoulos-Soares I, Chartoumpekis D, Kyriazopoulou V, Zaravinos A . EMT Factors and Metabolic Pathways in Cancer. Front Oncol. 2020; 10:499. PMC: 7154126. DOI: 10.3389/fonc.2020.00499. View

12.

Meng J, Chen S, Han J, Qian B, Wang X, Zhong W . Twist1 Regulates Vimentin through Cul2 Circular RNA to Promote EMT in Hepatocellular Carcinoma. Cancer Res. 2018; 78(15):4150-4162. DOI: 10.1158/0008-5472.CAN-17-3009. View

13.

Orso F, Quirico L, Dettori D, Coppo R, Virga F, Ferreira L . Role of miRNAs in tumor and endothelial cell interactions during tumor progression. Semin Cancer Biol. 2019; 60:214-224. DOI: 10.1016/j.semcancer.2019.07.024. View

14.

Li R, Dong B, Wang Z, Jiang T, Chen G . RETRACTED: MicroRNA-361-5p inhibits papillary thyroid carcinoma progression by targeting ROCK1. Biomed Pharmacother. 2018; 102:988-995. DOI: 10.1016/j.biopha.2018.03.122. View

15.

Ji Q, Li Y, Zhao Q, Fan L, Tan B, Zhang Z . KLF11 promotes gastric cancer invasion and migration by increasing Twist1 expression. Neoplasma. 2018; 66(1):92-100. DOI: 10.4149/neo_2018_180325N201. View

16.

Rupaimoole R, Calin G, Lopez-Berestein G, Sood A . miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. Cancer Discov. 2016; 6(3):235-46. PMC: 4783232. DOI: 10.1158/2159-8290.CD-15-0893. View

17.

Malkowski P, Pacholczyk M, Lagiewska B, Adadynski L, Wasiak D, Kwiatkowski A . [Hepatocellular carcinoma--epidemiology and treatment]. Przegl Epidemiol. 2007; 60(4):731-40. View

18.

Haga C, Phinney D . MicroRNAs in the imprinted DLK1-DIO3 region repress the epithelial-to-mesenchymal transition by targeting the TWIST1 protein signaling network. J Biol Chem. 2012; 287(51):42695-707. PMC: 3522270. DOI: 10.1074/jbc.M112.387761. View

19.

Forner A, Reig M, Bruix J . Hepatocellular carcinoma. Lancet. 2018; 391(10127):1301-1314. DOI: 10.1016/S0140-6736(18)30010-2. View

20.

Zhu Y, Qu C, Hong X, Jia Y, Lin M, Luo Y . Trabid inhibits hepatocellular carcinoma growth and metastasis by cleaving RNF8-induced K63 ubiquitination of Twist1. Cell Death Differ. 2018; 26(2):306-320. PMC: 6329825. DOI: 10.1038/s41418-018-0119-2. View